Genistein in polycystic ovary syndrome: mechanisms, preclinical evidence, and translational potential
Abstract
Polycystic ovary syndrome (PCOS) is a prevalent reproductive-endocrine disorder in reproductive-aged women. Due to the lack of radical cure, multi-target therapeutic strategies are urgently needed. Genistein, a soy-derived phytoestrogen, exhibits pleiotropic biological activities and is a promising adjuvant candidate for PCOS. Accumulating studies suggests that genistein may improves insulin sensitivity, regulates reproductive hormones, promotes follicular development, and alleviates oxidative stress and chronic inflammation, thereby ameliorating PCOS symptoms. This review summarizes the therapeutic effects, molecular mechanisms, preclinical evidence, and clinical translation prospects of genistein in PCOS, providing a theoretical basis for its clinical application. However, significant challenges remain in translating this research into clinical practice. These include the limited availability of data from human clinical trials, the lack of a clearly defined optimal dosage and administration regimen, insufficient evidence regarding long-term safety, and the potential for variations in bioavailability and individual metabolism to impact efficacy. Addressing these limitations is critical for advancing genistein toward future clinical application.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.